Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brunswick Corporation (BC) vs Medpace Holdings Inc (MEDP) Price & Performance

Brunswick CorporationTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Brunswick Corporation vs Medpace Holdings Inc — how do they compare? Brunswick Corporation trades at $81.32 (market cap $5.28B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 3.2× Brunswick Corporation's market cap, and Brunswick Corporation pays a 2.16% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

BCMEDP
Market Cap
$5.28B$16.90B
Sector
Consumer CyclicalTechnology
52-Week High
$89.22$620.59
52-Week Low
$58.75$393.42
Enterprise Value
$7.28B$16.52B
Dividend Yield
2.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brunswick Corporation

Brunswick Corporation (BC) trades at $79.54, down 1.11% on the day, with strong analyst support showing 22 buy ratings and a consensus price target of $85.33. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company posted a net loss of $137.3 million in 2025. Technical indicators show a bullish trend with support at $80 and resistance at $82, while fundamentals reveal mixed profitability with negative margins but positive cash flow from operations of $562.1 million.

The outlook remains cautiously optimistic given strong institutional backing and recent earnings beats, though investors face risks from negative profit margins and elevated P/E ratio of 73.92. The stock offers potential upside to analyst targets but requires monitoring of profitability improvements and debt management amid competitive pressures in the marine industry.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brunswick Corporation

Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines

Read more on BC

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP